Riccardo Bixio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Riccardo Bixio has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Maurizio Rossini
Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy
13 shared publications - Davide Bertelle
Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy
9 shared publications - Giovanni Adami
Rheumatology Unit, University of Verona
8 shared publications Maurizio Rossini
Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy
8 shared publications- Ombretta Viapiana
Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy
8 shared publications Ombretta Viapiana
Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy
7 shared publications
Latest Publications
- 15 September 2025
- Published by BMJ in Journal of Scleroderma and Related Disorders
- Vol. 10 (3) , 425-433
Ultrasonographic assessment of digital ulcers in systemic sclerosis: Quantitative and qualitative insights for evaluation and follow-up
Objective: The objective of this study is to examine the efficacy of ultrasonography in evaluating and tracking the healing process of digital ulcers in patients with systemic sclerosis. Methods: The study cohort comprised 23 patients with systemic sclerosis and digital ulcers. Gray Scale and Power Doppler ultrasonography was employed for the assessment of lesions. Subsequently, a sharp debridement was administered, followed by the application of hydrocolloid dressings. The healing process was then monitored through follow-up and using ultrasonography. Results: Of the 46 ulcers observed, 34 demonstrated complete healing, while 12 did not. The use of Power Doppler ultrasonography was found to be a highly significant indicator of healing. Significant statistical differences were observed in lesion dimensions (length, width, depth) between the healed and non-healed groups and a strong correlation was observed between the reduction in lesion dimensions and the healing process. The results of the point-biserial correlation analysis indicated a robust positive correlation between healing and alterations in length (r = 0.600) and width (r = 0.576), and a moderate positive correlation with depth (r = 0.400). Conclusion: The findings of this study indicate that the ultrasonography is a feasible and objective method to assess digital ulcers and their healing. Reduction of length and width and presence of Power Doppler ultrasonography are strong indicators of wound repair. Furthermore, the presence of necrotic tissue is not an indicator for a poor outcome. Ultrasonography offers comprehensive qualitative and quantitative data that facilitate a deeper comprehension and monitoring of the healing process.
- 15 September 2025
- Published by BMJ in Journal of Scleroderma and Related Disorders
- Vol. 10 (3) , 425-433
Ultrasonographic assessment of digital ulcers in systemic sclerosis: Quantitative and qualitative insights for evaluation and follow-up
Objective: The objective of this study is to examine the efficacy of ultrasonography in evaluating and tracking the healing process of digital ulcers in patients with systemic sclerosis. Methods: The study cohort comprised 23 patients with systemic sclerosis and digital ulcers. Gray Scale and Power Doppler ultrasonography was employed for the assessment of lesions. Subsequently, a sharp debridement was administered, followed by the application of hydrocolloid dressings. The healing process was then monitored through follow-up and using ultrasonography. Results: Of the 46 ulcers observed, 34 demonstrated complete healing, while 12 did not. The use of Power Doppler ultrasonography was found to be a highly significant indicator of healing. Significant statistical differences were observed in lesion dimensions (length, width, depth) between the healed and non-healed groups and a strong correlation was observed between the reduction in lesion dimensions and the healing process. The results of the point-biserial correlation analysis indicated a robust positive correlation between healing and alterations in length (r = 0.600) and width (r = 0.576), and a moderate positive correlation with depth (r = 0.400). Conclusion: The findings of this study indicate that the ultrasonography is a feasible and objective method to assess digital ulcers and their healing. Reduction of length and width and presence of Power Doppler ultrasonography are strong indicators of wound repair. Furthermore, the presence of necrotic tissue is not an indicator for a poor outcome. Ultrasonography offers comprehensive qualitative and quantitative data that facilitate a deeper comprehension and monitoring of the healing process.
- Open Access
- 8 September 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (4) , rkaf094
Guselkumab effectiveness in real-world settings: observations from an Italian multicentre study
Objectives: Guselkumab is a biologic disease-modifying antirheumatic drug (bDMARD) with proven efficacy for psoriatic arthritis (PsA) in randomized controlled trials. Evidence of its effectiveness from clinical practice remains limited. We evaluated the real-world effectiveness of guselkumab for PsA (primary objective) and identified factors influencing clinical outcomes. Methods: This retrospective, observational, multicentre study enrolled consecutive patients with PsA prescribed guselkumab for joint involvement at 26 Italian rheumatology referral centres. Baseline data included patient history, PsA subtype, treatment history and disease activity. Treatment effectiveness was assessed with Kaplan–Meier curves; Cox proportional hazards analysis identified factors associated with treatment persistence. Results: The study included 278 patients (median age: 57 years [interquartile range, IQR: 50–63]; 64.4% female); median observation 10.7 months (IQR: 5.3–15.9; total: 3332.6 patient-months). Retention rates at 6, 12 and 24 months were 90.4%, 80.0% and 67.8%, respectively. Reasons for discontinuation included primary inefficacy (48% of 54 cases), secondary inefficacy (41%) and skin/mucosal intolerance (4%). Statistically significant factors (P < 0.05) influencing treatment persistence included sex, smoking, concurrent conventional synthetic DMARDs (csDMARDs), corticosteroid use, year of prescription and axial or enthesitic involvement. Conclusions: Approximately two-thirds of PsA patients treated with guselkumab remained on therapy after 2 years. Adverse events motivated <10% of discontinuations. Effectiveness was higher in patients with enthesitic or axial PsA and in those without concurrent corticosteroids or csDMARDs, confirming the effectiveness and safety of guselkumab as an optimal choice for monotherapy, particularly in PsA patients with enthesitis, with or without joint impairment, and/or axial involvement.
- 8 September 2025
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 9 (4) , rkaf094
Open AccessGuselkumab effectiveness in real-world settings: observations from an Italian multicentre study
Objectives: Guselkumab is a biologic disease-modifying antirheumatic drug (bDMARD) with proven efficacy for psoriatic arthritis (PsA) in randomized controlled trials. Evidence of its effectiveness from clinical practice remains limited. We evaluated the real-world effectiveness of guselkumab for PsA (primary objective) and identified factors influencing clinical outcomes. Methods: This retrospective, observational, multicentre study enrolled consecutive patients with PsA prescribed guselkumab for joint involvement at 26 Italian rheumatology referral centres. Baseline data included patient history, PsA subtype, treatment history and disease activity. Treatment effectiveness was assessed with Kaplan–Meier curves; Cox proportional hazards analysis identified factors associated with treatment persistence. Results: The study included 278 patients (median age: 57 years [interquartile range, IQR: 50–63]; 64.4% female); median observation 10.7 months (IQR: 5.3–15.9; total: 3332.6 patient-months). Retention rates at 6, 12 and 24 months were 90.4%, 80.0% and 67.8%, respectively. Reasons for discontinuation included primary inefficacy (48% of 54 cases), secondary inefficacy (41%) and skin/mucosal intolerance (4%). Statistically significant factors (P < 0.05) influencing treatment persistence included sex, smoking, concurrent conventional synthetic DMARDs (csDMARDs), corticosteroid use, year of prescription and axial or enthesitic involvement. Conclusions: Approximately two-thirds of PsA patients treated with guselkumab remained on therapy after 2 years. Adverse events motivated <10% of discontinuations. Effectiveness was higher in patients with enthesitic or axial PsA and in those without concurrent corticosteroids or csDMARDs, confirming the effectiveness and safety of guselkumab as an optimal choice for monotherapy, particularly in PsA patients with enthesitis, with or without joint impairment, and/or axial involvement.
- 10 May 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (9) , 5193-5195
Intensive therapeutic plasma exchange in life-threatening ANCA-associated vasculitis
- 10 May 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (9) , 5193-5195
Intensive therapeutic plasma exchange in life-threatening ANCA-associated vasculitis
- Open Access
- 4 March 2025
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 27 (1) , 1-18
Ultrasound Beyond Joints: A Review of Extra-Articular Applications in Rheumatology
Purpose of Review: This review highlights key ultrasound applications for evaluating extra-articular involvement in rheumatic diseases, including the lungs, vessels, salivary glands, muscles, nerves, skin, and nails. It explores recent advances, emerging areas of assessment, and future research directions. Additionally, the review examines current limitations in the routine use of ultrasound for these purposes and considers the potential of new technologies, such as shear-wave elastography, contrast-enhanced ultrasound, and artificial intelligence, to enhance the early detection and monitoring of extra-articular manifestations in rheumatic diseases. Recent Findings: Extra-articular manifestations in patients with rheumatic diseases are crucial for diagnosis, management (including treatment strategies), and prognosis, making accurate assessment essential. Growing evidence supports the role of ultrasound in assessing these manifestations for diagnosis, monitoring, and gaining insights into disease pathogenesis. Recent studies emphasize the significant utility of ultrasound in evaluating extra-articular involvement across various organ systems, including the lungs, vessels, salivary glands, muscles, nerves, skin, and nails. Technological advances, such as shear-wave elastography, contrast-enhanced ultrasound, and artificial intelligence, are expanding the scope and precision of ultrasound applications. Despite its potential, challenges such as operator dependency, lack of standardized protocols, and the need for specialized training hinder its widespread adoption. Summary: Ultrasound is a non-invasive, cost-effective, and radiation-free imaging modality with high diagnostic accuracy, making it a valuable tool for assessing extra-articular manifestations in rheumatic diseases. Emerging technologies may further enhance its clinical utility. However, efforts to standardize techniques and improve accessibility are necessary to optimize its integration into routine practice.
- 4 March 2025
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 27 (1) , 1-18
Open AccessUltrasound Beyond Joints: A Review of Extra-Articular Applications in Rheumatology
Purpose of Review: This review highlights key ultrasound applications for evaluating extra-articular involvement in rheumatic diseases, including the lungs, vessels, salivary glands, muscles, nerves, skin, and nails. It explores recent advances, emerging areas of assessment, and future research directions. Additionally, the review examines current limitations in the routine use of ultrasound for these purposes and considers the potential of new technologies, such as shear-wave elastography, contrast-enhanced ultrasound, and artificial intelligence, to enhance the early detection and monitoring of extra-articular manifestations in rheumatic diseases. Recent Findings: Extra-articular manifestations in patients with rheumatic diseases are crucial for diagnosis, management (including treatment strategies), and prognosis, making accurate assessment essential. Growing evidence supports the role of ultrasound in assessing these manifestations for diagnosis, monitoring, and gaining insights into disease pathogenesis. Recent studies emphasize the significant utility of ultrasound in evaluating extra-articular involvement across various organ systems, including the lungs, vessels, salivary glands, muscles, nerves, skin, and nails. Technological advances, such as shear-wave elastography, contrast-enhanced ultrasound, and artificial intelligence, are expanding the scope and precision of ultrasound applications. Despite its potential, challenges such as operator dependency, lack of standardized protocols, and the need for specialized training hinder its widespread adoption. Summary: Ultrasound is a non-invasive, cost-effective, and radiation-free imaging modality with high diagnostic accuracy, making it a valuable tool for assessing extra-articular manifestations in rheumatic diseases. Emerging technologies may further enhance its clinical utility. However, efforts to standardize techniques and improve accessibility are necessary to optimize its integration into routine practice.
- 3 February 2025
- Published by Oxford University Press (OUP) in Rheumatology
Comment on: Vasculitis associated with VEXAS syndrome
- 3 February 2025
- Published by Oxford University Press (OUP) in Rheumatology
Comment on: Vasculitis associated with VEXAS syndrome
- 9 December 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (1) , 299-304
Barnidipine as a potential alternative treatment for Raynaud's phenomenon secondary to systemic sclerosis: a retrospective pilot study
Objectives To assess short-term barnidipine efficacy and tolerability on Systemic Sclerosis (SSc)-Raynaud’s phenomenon (RP). Methods We retrospectively evaluated patients with SSc starting barnidipine 10 mg/day. Raynaud’s Condition Score (RCS) and mean blood pressure (MBP) were assessed at baseline and 6-month follow-up. Discontinuation rates and adverse events (AEs) were compared with retrospectively evaluated patients who started MR-nifedipine 20 mg/day at our centre. Results Sixty-four patients (29 barnidipine, 35 MR-nifedipine) were evaluated. Most patients starting barnidipine had a previous CCB exposure (69%; 57.9% of these were withdrawn for AEs). During follow-up, RCS decreased significantly (6.6 ± 1.8 vs 4.4 ± 1.8, p < 0.001), while the MBP did not change significantly (86.4 ± 8.4 vs 85 ± 7.3 mmHg; p = 0.36). Nine patients (31%) discontinued barnidipine during the follow-up (AEs 6/9, inefficacy 3/9). Previous CCB failure did not predict barnidipine withdrawal (OR = 0.188 95%CI [0.02–1.8]; p = 0.147). No predictors of barnidipine withdrawal were found, and no clinical or demographic differences were found between patients withdrawing and continuing barnidipine. The 6-month retention rates of barnidipine and MR-nifedipine did not differ significantly (69 vs 80%; log-rank p = 0.23), and the two groups had a similar incidence of AEs leading to discontinuation (20.1 vs 17%; p = 0.48). Conclusions Barnidipine could be an effective and well-tolerated therapeutic option to treat SSc-RP, even in patients previously failing other CCBs. Key Points • Calcium channel blockers (CCBs) currently represent the first-line treatment for Raynaud’s phenomenon secondary to Systemic Sclerosis (SSc-RP). However, little data exists about using novel CCBs, such as barnidipine, in this condition. • This study retrospectively evaluated patients with SSc-RP treated with barnidipine to assess its short-term efficacy. To serve as a control group for tolerability, we retrospectively compared these patients with others starting modified release-nifedipine (MR-nifedipine). • In patients treated with barnidipine, we observed a significant decrease in Raynaud’s condition score at the 6-month follow-up without substantial changes in mean blood pressure. • The proportion of adverse events and drug withdrawal rate between patients starting barnidipine and MR-nifedipine did not differ significantly, even in patients starting barnidipine after previously failing other CCBs.
- 9 December 2024
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (1) , 299-304
Barnidipine as a potential alternative treatment for Raynaud's phenomenon secondary to systemic sclerosis: a retrospective pilot study
Objectives To assess short-term barnidipine efficacy and tolerability on Systemic Sclerosis (SSc)-Raynaud’s phenomenon (RP). Methods We retrospectively evaluated patients with SSc starting barnidipine 10 mg/day. Raynaud’s Condition Score (RCS) and mean blood pressure (MBP) were assessed at baseline and 6-month follow-up. Discontinuation rates and adverse events (AEs) were compared with retrospectively evaluated patients who started MR-nifedipine 20 mg/day at our centre. Results Sixty-four patients (29 barnidipine, 35 MR-nifedipine) were evaluated. Most patients starting barnidipine had a previous CCB exposure (69%; 57.9% of these were withdrawn for AEs). During follow-up, RCS decreased significantly (6.6 ± 1.8 vs 4.4 ± 1.8, p < 0.001), while the MBP did not change significantly (86.4 ± 8.4 vs 85 ± 7.3 mmHg; p = 0.36). Nine patients (31%) discontinued barnidipine during the follow-up (AEs 6/9, inefficacy 3/9). Previous CCB failure did not predict barnidipine withdrawal (OR = 0.188 95%CI [0.02–1.8]; p = 0.147). No predictors of barnidipine withdrawal were found, and no clinical or demographic differences were found between patients withdrawing and continuing barnidipine. The 6-month retention rates of barnidipine and MR-nifedipine did not differ significantly (69 vs 80%; log-rank p = 0.23), and the two groups had a similar incidence of AEs leading to discontinuation (20.1 vs 17%; p = 0.48). Conclusions Barnidipine could be an effective and well-tolerated therapeutic option to treat SSc-RP, even in patients previously failing other CCBs. Key Points • Calcium channel blockers (CCBs) currently represent the first-line treatment for Raynaud’s phenomenon secondary to Systemic Sclerosis (SSc-RP). However, little data exists about using novel CCBs, such as barnidipine, in this condition. • This study retrospectively evaluated patients with SSc-RP treated with barnidipine to assess its short-term efficacy. To serve as a control group for tolerability, we retrospectively compared these patients with others starting modified release-nifedipine (MR-nifedipine). • In patients treated with barnidipine, we observed a significant decrease in Raynaud’s condition score at the 6-month follow-up without substantial changes in mean blood pressure. • The proportion of adverse events and drug withdrawal rate between patients starting barnidipine and MR-nifedipine did not differ significantly, even in patients starting barnidipine after previously failing other CCBs.
- 9 October 2024
- Published by BMJ in Journal of Scleroderma and Related Disorders
- Vol. 10 (2) , 156-162
Efficacy and safety of digital nerve block for pain management during sharp debridement of digital ulcers in systemic sclerosis: A prospective observational study
Introduction: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis and vascular abnormalities, often leading to the development of digital ulcers (DUs). DUs are painful and debilitating, significantly impacting patients’ quality of life. Effective pain management during debridement is crucial, yet there is no consensus on the optimal approach. This study evaluates the efficacy and safety of digital nerve block (DNB) using lidocaine and mepivacaine for pain control during sharp debridement of DUs in SSc patients. Methods: This prospective observational study was conducted from September 2023 to May 2024 at the Rheumatology Operating Unit, University of Verona. Patients were randomized to receive either 1 mL of 2% lidocaine or 2% mepivacaine for DNB. Pain levels were assessed using a categorical grading scale during the injection and debridement. The outcomes were pain control and performance of lidocaine versus mepivacaine. Results: The cohort developed 46 ulcers. The pain was abolished in almost all patients. Lidocaine achieved faster anaesthesia (127.92 ± 34.32 s) compared with mepivacaine (252.65 ± 49.89 s, p < 0.001). Mepivacaine resulted in less pain during injection ( p = 0.006). No significant difference in pain levels during debridement was observed between the two anaesthetics. Three mild adverse effects (Raynaud’s phenomenon) were reported. All procedures were completed successfully, and 35 ulcers healed with a mean time of 6.1 ± 7.77 weeks. Conclusions: DNB with mepivacaine provides effective pain control during DU debridement in SSc patients, with lower injection site pain and comparable efficacy to lidocaine. The procedure is safe, well-tolerated and facilitates successful ulcer healing. Further studies with larger cohorts are warranted to confirm these findings.
- 9 October 2024
- Published by BMJ in Journal of Scleroderma and Related Disorders
- Vol. 10 (2) , 156-162
Efficacy and safety of digital nerve block for pain management during sharp debridement of digital ulcers in systemic sclerosis: A prospective observational study
Introduction: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis and vascular abnormalities, often leading to the development of digital ulcers (DUs). DUs are painful and debilitating, significantly impacting patients’ quality of life. Effective pain management during debridement is crucial, yet there is no consensus on the optimal approach. This study evaluates the efficacy and safety of digital nerve block (DNB) using lidocaine and mepivacaine for pain control during sharp debridement of DUs in SSc patients. Methods: This prospective observational study was conducted from September 2023 to May 2024 at the Rheumatology Operating Unit, University of Verona. Patients were randomized to receive either 1 mL of 2% lidocaine or 2% mepivacaine for DNB. Pain levels were assessed using a categorical grading scale during the injection and debridement. The outcomes were pain control and performance of lidocaine versus mepivacaine. Results: The cohort developed 46 ulcers. The pain was abolished in almost all patients. Lidocaine achieved faster anaesthesia (127.92 ± 34.32 s) compared with mepivacaine (252.65 ± 49.89 s, p < 0.001). Mepivacaine resulted in less pain during injection ( p = 0.006). No significant difference in pain levels during debridement was observed between the two anaesthetics. Three mild adverse effects (Raynaud’s phenomenon) were reported. All procedures were completed successfully, and 35 ulcers healed with a mean time of 6.1 ± 7.77 weeks. Conclusions: DNB with mepivacaine provides effective pain control during DU debridement in SSc patients, with lower injection site pain and comparable efficacy to lidocaine. The procedure is safe, well-tolerated and facilitates successful ulcer healing. Further studies with larger cohorts are warranted to confirm these findings.
- Open Access
- 9 September 2024
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 19 (8) , 2331-2345
The role of 18FDG–PET imaging in VEXAS syndrome: a multicentric case series and a systematic review of the literature
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic) syndrome is characterized by heterogeneous clinical manifestations. Due to the inflammatory nature of this condition, 18-FDG–PET (18-fluorodeoxyglucose–positron emission tomography) might be used to diagnose and monitor the disease. However, no data are available about the most common findings of PET imaging in this disease. For this reason, we summarised all the available reports of patients with VEXAS who underwent at least one PET scan and described 8 additional patients’ PET from our centres. Overall, we described 35 patients’ PET findings. All patients were male, with a median age of 70 years. The most frequent hypermetabolic sites on PET scans were the bone marrow (77.1%), lymph nodes (35.3%), lungs (28.6%), spleen and large vessels (22.9%), and cartilage (20%). Six patients underwent a PET scan 2.7 ± 1.5 years before VEXAS diagnosis, showing nonspecific uptake in the bone marrow. Four patients had a follow-up PET scan, showing a decrease or a disappearance of the previously identified hypermetabolic areas. In conclusion, although no specific uptake site has been found for VEXAS syndrome, PET imaging could help detect inflammatory foci that are not clinically evident. In addition, high metabolic activity in bone marrow might precede the clinical onset of the disease, shedding light on the pathogenesis of VEXAS.
- 9 September 2024
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 19 (8) , 2331-2345
Open AccessThe role of 18FDG–PET imaging in VEXAS syndrome: a multicentric case series and a systematic review of the literature
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic) syndrome is characterized by heterogeneous clinical manifestations. Due to the inflammatory nature of this condition, 18-FDG–PET (18-fluorodeoxyglucose–positron emission tomography) might be used to diagnose and monitor the disease. However, no data are available about the most common findings of PET imaging in this disease. For this reason, we summarised all the available reports of patients with VEXAS who underwent at least one PET scan and described 8 additional patients’ PET from our centres. Overall, we described 35 patients’ PET findings. All patients were male, with a median age of 70 years. The most frequent hypermetabolic sites on PET scans were the bone marrow (77.1%), lymph nodes (35.3%), lungs (28.6%), spleen and large vessels (22.9%), and cartilage (20%). Six patients underwent a PET scan 2.7 ± 1.5 years before VEXAS diagnosis, showing nonspecific uptake in the bone marrow. Four patients had a follow-up PET scan, showing a decrease or a disappearance of the previously identified hypermetabolic areas. In conclusion, although no specific uptake site has been found for VEXAS syndrome, PET imaging could help detect inflammatory foci that are not clinically evident. In addition, high metabolic activity in bone marrow might precede the clinical onset of the disease, shedding light on the pathogenesis of VEXAS.
- Open Access
- 21 August 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (4) , 1698-1704
Glucocorticoid sparing effect of Janus kinase inhibitors compared to biologic disease modifying anti-rheumatic drugs in rheumatoid arthritis, a single-centre retrospective analysis
Glucocorticoid sparing in rheumatoid arthritis (RA) treatment is crucial to minimizing adverse effects associated with long-term use. Janus kinase inhibitors (JAKi) could potentially offer a more potent glucocorticoid-sparing effect than biological Disease-Modifying Antirheumatic Drugs (bDMARDs) This is a single-center retrospective analysis of RA patients treated with JAKi or bDMARDs. Glucocorticoid tapering, rescue therapy and discontinuation were analyzed through mixed-effects models, Poisson regression, and multivariable logistic regression, respectively, adjusting for baseline disease activity, demographic factors, and treatment line. A total of 716 RA patients treated with JAKi (n = 156) or bDMARDs (n = 560) were evaluated. JAKi treatment was associated with a more rapid reduction in glucocorticoid dose within the first 6 months and 60% higher odds of discontinuation compared with bDMARDs (adjusted odds ratio 1.63, 95% CI 1.02–2.60, p 0.039). Despite a higher baseline glucocorticoid dose, over 50% of JAKi-treated patients discontinued glucocorticoids after 12 months, vs ∼40% for bDMARDs. The need for glucocorticoid rescue therapy was significantly higher in the bDMARD group (rate ratio 2.66 (95% CI, 1.88–3.74)). Our findings indicate that JAK inhibitors facilitate more rapid glucocorticoid tapering compared with bDMARDs in RA patients. These results underscore the potential of JAK inhibitors to reduce long-term glucocorticoid exposure, highlighting their value in RA management strategies, including minimizing glucocorticoid-related adverse effects.
- 21 August 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (4) , 1698-1704
Open AccessGlucocorticoid sparing effect of Janus kinase inhibitors compared to biologic disease modifying anti-rheumatic drugs in rheumatoid arthritis, a single-centre retrospective analysis
Glucocorticoid sparing in rheumatoid arthritis (RA) treatment is crucial to minimizing adverse effects associated with long-term use. Janus kinase inhibitors (JAKi) could potentially offer a more potent glucocorticoid-sparing effect than biological Disease-Modifying Antirheumatic Drugs (bDMARDs) This is a single-center retrospective analysis of RA patients treated with JAKi or bDMARDs. Glucocorticoid tapering, rescue therapy and discontinuation were analyzed through mixed-effects models, Poisson regression, and multivariable logistic regression, respectively, adjusting for baseline disease activity, demographic factors, and treatment line. A total of 716 RA patients treated with JAKi (n = 156) or bDMARDs (n = 560) were evaluated. JAKi treatment was associated with a more rapid reduction in glucocorticoid dose within the first 6 months and 60% higher odds of discontinuation compared with bDMARDs (adjusted odds ratio 1.63, 95% CI 1.02–2.60, p 0.039). Despite a higher baseline glucocorticoid dose, over 50% of JAKi-treated patients discontinued glucocorticoids after 12 months, vs ∼40% for bDMARDs. The need for glucocorticoid rescue therapy was significantly higher in the bDMARD group (rate ratio 2.66 (95% CI, 1.88–3.74)). Our findings indicate that JAK inhibitors facilitate more rapid glucocorticoid tapering compared with bDMARDs in RA patients. These results underscore the potential of JAK inhibitors to reduce long-term glucocorticoid exposure, highlighting their value in RA management strategies, including minimizing glucocorticoid-related adverse effects.
- 12 June 2024
- Published by Elsevier in Joint Bone Spine
- Vol. 91 (6) , 105747
Discontinuation of infliximab leading to auditory loss in a patient with Cogan syndrome: A case report
- 12 June 2024
- Published by Elsevier in Joint Bone Spine
- Vol. 91 (6) , 105747
Discontinuation of infliximab leading to auditory loss in a patient with Cogan syndrome: A case report